GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (MEX:BMRN) » Definitions » Price-to-Funds-From-Operations

Biomarin Pharmaceutical (MEX:BMRN) Price-to-Funds-From-Operations : (As of Mar. 02, 2025)


View and export this data going back to 2019. Start your Free Trial

What is Biomarin Pharmaceutical Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Biomarin Pharmaceutical Business Description

Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.